Hemodynamics, fluids & transfusion

A Propensity-Matched Cohort Study of Intravenous Iron versus Red Cell Transfusions for Preoperative Iron-Deficiency Anemia

Anesth AnalgPublished Retrospective cohort study

Main finding · Postoperative mortalityResult — go to the resultRelative risk 0.63 95% CI 0.60–0.66

Authors' conclusion

In a risk-adjusted analysis, preoperative IDA treatment with IV iron compared to RBC transfusion was associated with a reduction in 30-day postoperative mortality and morbidity, a higher 30-day postoperative hemoglobin level, and reduced postoperative RBC transfusion.

Study context

Population
Surgical patients diagnosed with iron-deficiency anemia (IDA) within 3 months preoperatively, 2003–2023propensity-matched cohorts
Participants
77,179 vs 77,179
Exposure
Preoperative intravenous (IV) iron vs preoperative RBC transfusion
  • IV ironn = 77,179
  • RBC transfusionn = 77,179reference
Outcome
Postoperative mortality
Follow-up
30 days
Methodological detailspropensity-score matched, national database (TriNetX Research Network)
  • Propensity-score matched
  • National database (TriNetX Research Network)

Main finding

As reported in the abstract

Relative risk

0.63

95% CI 0.60–0.66

P = 0.001

Events by group

IV iron vs RBC transfusion
RR 0.63 (95% CI 0.60–0.66); P = 0.001

Observational data: associations, not effects.

Secondary outcomes

OutcomeIV ironRBC transfusionRR (95% CI)P value
Postoperative composite morbidity · 30 daysAfter Bonferroni adjustment18.4%24.1%0.76 (0.75–0.78)P = 0.001
Postoperative RBC transfusion · 30 days4.9%16.4%0.30 (0.29–0.31)

Postoperative hemoglobin · 30-day postoperative period · after Bonferroni adjustment

P = 0.001

Original publication

A Propensity-Matched Cohort Study of Intravenous Iron versus Red Cell Transfusions for Preoperative Iron-Deficiency Anemia. Anesth Analg. Published 22 July 2024. doi:10.1213/ane.0000000000006974

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.